Evidence map›Paper›PMID 34997152›Full record

ArticleScientific reports2022

A comprehensive analysis of selected medicines collected from private drug outlets of Dhaka city, Bangladesh in a simple random survey.

Mohammad Sofiqur Rahman, Naoko Yoshida, Hirohito Tsuboi, James Regun Karmoker, Nadia Kabir, Simon Schaefermann, Yoshio Akimoto, Mohiuddin Ahmed Bhuiyan, Md Selim Reza, Kazuko Kimura

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Mohammad Sofiqur RahmanMedi-Quality Security Institute (MQS), Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-1192, Japan. rahmansofique@staff.kanazawa-u.ac.jp.
Naoko YoshidaAI Hospital/Macro Signal Dynamics Research and Development Center, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan. naoko@p.kanazawa-u.ac.jp.
Hirohito TsuboiDepartment of Clinical Pharmacy and Healthcare Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
James Regun KarmokerUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Nadia KabirDepartment of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, Dhaka, 1205, Bangladesh.
Simon SchaefermannPharmaceutical Institute, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Yoshio AkimotoMedi-Quality Security Institute (MQS), Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
Mohiuddin Ahmed BhuiyanDepartment of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, Dhaka, 1205, Bangladesh.
Md Selim RezaDepartment of Pharmaceutical Technology, University of Dhaka, Dhaka, 1000, Bangladesh.
Kazuko KimuraMedi-Quality Security Institute (MQS), Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
Kanazawa University · JPUniversity of Asia Pacific · BDUniversity of Dhaka · BDUniversity of Oklahoma Health Sciences Center · USUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive data are needed to prevent substandard and falsified (SF) medicines as they pose a major risk to human health. To assess the quality of selected medicines, samples were collected from random private drug outlets of Dhaka North and South City Corporation, Bangladesh. Sample analysis included visual observation of the packaging, authenticity of the samples, legitimacy and registration verification of the manufacturer, physicochemical analysis, and price. Chemical analysis of the samples was performed using a portable Raman spectroscopy and high-performance liquid chromatography according to the pharmacopoeia. Several discrepancies were noted in the visual observation of samples. Among the 189 collected samples of esomeprazole (ESM), cefixime (CFIX), and amoxicillin-clavulanic acid (CVA-AMPC), 21.2% were confirmed to be authentic, 91.3% manufacturers were confirmed legitimate, and 2.1% of all samples were unregistered. Chemical analysis of the samples revealed that 9.5% (95% CI 5.7-14.6) of samples were SFs. Falsified samples and quality variation in the same generic branded samples were both detected by Raman spectroscopic analysis. Overall, sample prices were satisfactory relative to the international reference price. This study documents the availability of poor-quality medicines, demonstrating the need for immediate attention by the national medicine regulatory authority.

Indexed as

BangladeshCommerceDrug ContaminationDrug PackagingDrugs, GenericQuality ControlDrugs, Generic

Identifiers

PMID34997152
PMCPMC8741935
OpenAlexW4206541403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.